Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial

OBJECTIVE: Randomized controlled trials comparing tocilizumab and baricitinib in patients with coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized controlled trial aiming to address this unmet need. METHODS: To determine whether baricitinib was non-inferior to tocilizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Karampitsakos, Theodoros, Papaioannou, Ourania, Tsiri, Panagiota, Katsaras, Matthaios, Katsimpris, Andreas, Kalogeropoulos, Andreas P., Malakounidou, Elli, Zarkadi, Eirini, Tsirikos, Georgios, Georgiopoulou, Vasiliki, Sotiropoulou, Vasilina, Koulousousa, Electra, Chourpiliadi, Charikleia, Matsioulas, Apostolos, Lagadinou, Maria, Sampsonas, Fotios, Akinosoglou, Karolina, Marangos, Markos, Tzouvelekis, Argyris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636985/
https://www.ncbi.nlm.nih.gov/pubmed/36273769
http://dx.doi.org/10.1016/j.cmi.2022.10.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636985/
https://www.ncbi.nlm.nih.gov/pubmed/36273769
http://dx.doi.org/10.1016/j.cmi.2022.10.015

Ejemplares similares